Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model
- PMID: 17929276
- DOI: 10.1002/pros.20579
Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model
Abstract
Background: The transgenic adenocarcinoma of mouse prostate (TRAMP) model has been extensively characterized at the histological and molecular levels, and has been shown to mimic significant features of human prostate cancer. However, the status of Nkx3.1 expression in the TRAMP model has not been elucidated.
Methods: Immunohistochemical analyses were performed using dorsal, lateral, and ventral prostate (VP) lobes from ages 6 to 30 weeks. Quantitative RT-PCR analyses were performed to determine relative mRNA expression.
Results: Heterogeneous loss of Nkx3.1 was observed in hyperplastic lesions of the ventral, dorsal, and lateral lobes. At 6 weeks of age, the ventral lobe displayed profound loss of Nkx3.1. Diminished Nkx3.1 protein was observed in well- to moderately-differentiated cancer lesions of all lobes. Poorly differentiated (PD) tumors stained negatively for Nkx3.1. Quantitative RT-PCR analyses revealed the presence of Nkx3.1 mRNA in each lobe at all ages, albeit reduced to variable levels.
Conclusions: These data suggest that disease progression in the TRAMP model may be driven by loss of function of Nkx3.1, in addition to p53 and Rb. Lobe-specific disease progression in the TRAMP model correlates with the reduction of Nkx3.1 protein. Regulation of Nkx3.1 expression during tumorigenesis appears to occur by post-transcriptional and post-translational mechanisms.
Similar articles
-
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.Cancer Res. 2006 Nov 15;66(22):10683-90. doi: 10.1158/0008-5472.CAN-06-0963. Cancer Res. 2006. PMID: 17108105
-
The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.Cancer Res. 1999 May 1;59(9):2203-9. Cancer Res. 1999. PMID: 10232609
-
Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.Cancer Res. 2000 Nov 1;60(21):6111-5. Cancer Res. 2000. PMID: 11085535
-
Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1.Ann N Y Acad Sci. 2005 Nov;1059:33-40. doi: 10.1196/annals.1339.018. Ann N Y Acad Sci. 2005. PMID: 16382041 Review.
-
Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.Dev Dyn. 2003 Dec;228(4):767-78. doi: 10.1002/dvdy.10397. Dev Dyn. 2003. PMID: 14648854 Review.
Cited by
-
Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis.Differentiation. 2008 Jul;76(6):717-27. doi: 10.1111/j.1432-0436.2008.00292.x. Epub 2008 Jun 28. Differentiation. 2008. PMID: 18557759 Free PMC article. Review.
-
Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich Kava fraction.Mol Carcinog. 2016 Dec;55(12):2291-2303. doi: 10.1002/mc.22469. Epub 2016 Feb 3. Mol Carcinog. 2016. PMID: 26840761 Free PMC article.
-
Transcriptional regulation of the Nkx3.1 gene in prostate luminal stem cell specification and cancer initiation via its 3' genomic region.J Biol Chem. 2017 Aug 18;292(33):13521-13530. doi: 10.1074/jbc.M117.788315. Epub 2017 Jul 5. J Biol Chem. 2017. PMID: 28679531 Free PMC article.
-
SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398. Oncotarget. 2015. PMID: 26624980 Free PMC article.
-
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.Genes (Basel). 2017 Feb 16;8(2):71. doi: 10.3390/genes8020071. Genes (Basel). 2017. PMID: 28212321 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous